Darinaparsin: First Approval

James E. Frampton

doi:10.1007/s40265-022-01795-z

2022-11-04

PRE

James E. Frampton *

DOI：10.1007/s40265-022-01795-z

原文链接

原文求助

摘要

En 中文

Darinaparsin (Darvias(R)), an organoarsenic drug, is a novel mitochondrial-targeted anticancer agent currently being developed by Solasia Pharma K.K for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan and is currently in clinical development for this indication in China, the USA and the EU. This article summarizes the milestones in the development of darinaparsin leading to this first approval for relapsed or refractory PTCL. [GRAPHICS] .

Keyword:

T-CELL LYMPHOMA

ARSENICAL DARINAPARSIN

PHASE-I

TRIAL

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Caffeine Raises Blood Pressure at Work

Psychosomatic Medicine

IF0

1998-01-01

PREAI

James D. Lane; Barbara G. Phillips-Bute; Carl F. Pieper

The Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems

MOLECULAR PHARMACOLOGY

IF3

2014-04-01

PREAI

Garnier, Nicolas; Redstone, Genevieve G. J.; Dahabieh, Michael S.; Nichol, Jessica N.; del Rincon, Sonia V.; Gu, Yuxuan; Bohle, D. Scott; Sun, Yan; Conklin, Douglas S.; Mann, Koren K.; Miller, Wilson H., Jr.

When closest is not always the best: The distributed p-median problem

Journal of the Operational Research Society

IF0

2019-12-12

PREAI

Jack Brimberg; Andrea Maier; Anita Schöbel

A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines

LEUKEMIA

IF13.4

2008-07-17

PREAI

Diaz, Z.; Mann, K. K.; Marcoux, S.; Kourelis, M.; Colombo, M.; Komarnitsky, P. B.; Miller, W. H., Jr.

The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models

CLINICAL CANCER RESEARCH

IF10.2

2014-11-30

OAAI

Ravi, Dashnamoorthy; Bhalla, Savita; Gartenhaus, Ronald B.; Crombie, Jennifer; Kandela, Irawati; Sharma, Jaya; Mazar, Andrew; Evens, Andrew M.

A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors

CLINICAL CANCER RESEARCH

IF10.2

2009-07-15

PREAI

Tsimberidou, Apostolia Maria; Camacho, Luis H.; Verstovsek, Srdan; Ng, Chaan; Hong, David S.; Uehara, Cynthia K.; Gutierrez, Catalina; Daring, Shawn; Stevens, Jan; Komarnitsky, Philip B.; Schwartz, Brian; Kurzrock, Razelle

A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

AMERICAN JOURNAL OF HEMATOLOGY

IF9.9

2011-11-12

OAAI

Hosein, Peter J.; Craig, Michael D.; Tallman, Martin S.; Boccia, Ralph V.; Hamilton, Brian L.; Lewis, Jonathan J.; Lossos, Izidore S.

Balloon-borne measurement of the aerosol size distribution from an Icelandic flood basalt eruption

Earth and Planetary Science Letters

IF0

2016-11-01

OAAI

D. Vignelles; T.J. Roberts; E. Carboni; E. Ilyinskaya; M. Pfeffer; P. Dagsson Waldhauserova; A. Schmidt; G. Berthet; F. Jegou; J.-B. Renard; H. Ólafsson; B. Bergsson; R. Yeo; N. Fannar Reynisson; R.G. Grainger; B. Galle; V. Conde; S. Arellano; T. Lurton; B. Coute; Vincent Duverger

Darinaparsin: a novel organic arsenical with promising anticancer activity

EXPERT OPINION ON INVESTIGATIONAL DRUGS

IF4.1

2009-10-23

PREAI

Mann, Koren K.; Wallner, Barbara; Lossos, Izidore S.; Miller, Wilson H., Jr.

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma

INVESTIGATIONAL NEW DRUGS

IF2.7

2009-06-30

PREAI

Wu, Jennifer; Henderson, Charles; Feun, Lynn; Van Veldhuizen, Peter; Gold, Philip; Zheng, Hui; Ryan, Theresa; Blaszkowsky, Lawrence S.; Chen, HaoBin; Costa, Max; Rosenzweig, Barry; Nierodzik, MaryLynn; Hochster, Howard; Muggia, Franco; Abbadessa, Giovanni; Lewis, Jonathan; Zhu, Andrew X.

查看更多内容